Skip to main content
. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236

Table 4.

Completed clinical trials of combining immune checkpoint inhibitors with locoregional therapies in HCC.

Treatment arms (n) Phase Disease Condition Results ClinicalTrials.gov Identifier
Tre + RFA or TACE (32) I/II Advanced HCC PR: 26.3%; 6 months PFS: 57.1%;
MTP: 7.4 months (95% CI: 4.7–19.4); median OS: 12.3 months (95% CI: 9.3–15.4)		 NCT01853618
Pem or Niv + thermal ablation (50) II Advanced HCC ORR:10% vs. 24% (Pem or Niv vs. Pem or Niv + thermal ablation); PFS: 5 months (95% CI, 2.9–7.1); MTP: 6.1 months (95% CI, 2.6–11.2); OS: 16.9 months (95% CI, 7.7–26.1) NCT03939975
Nivo + Y90-radioembolization (40) II Asian patients with advanced HCC ORR: 31%; DCR: 58.3%; median PFS: 4.6 months (95% CI 2.3–4.8); median OS: 15.1 months (95% CI 7.8–NE); 3/4 grade TRAEs: 11% NCT03033446

CI, confidence interval; DCR, disease control rate; HCC, hepatocellular carcinoma; MTP, median time to tumor progression; Niv, nivolumab; ORR, objective response rate; Pem, pembrolizumab; PFS, progression-free survival; PR, partial response; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TRAEs, treatment-related adverse events; Tre, tremelimumab; OS, overall survival.